@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix RNA: . @prefix hgnc: . @prefix geneProductOf: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:1527; a RNA: . sub:_2 occursIn: obo:CLO_0002042, species:9606; rdf:object sub:_1; rdf:predicate belv:increases; rdf:subject chebi:3722; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:cisplatin) -> r(HGNC:CAV1)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "20131211" . sub:_3 prov:value "In order to determine the functional targets of ATF2 and c-Jun, we analyzed the agreement of the ATF2/c-Jun promoter binding profile with gene expression using Affymetrix GeneChips. Total RNA of BT474 cells prepared 3 hr following treatment with cisplatin was analyzed. Of 9177 unique genes represented on the Affymetrix U95Av2 oligonucleotide array, 352 genes show significant change by the double criteria that fold change >|2| and p < 0.05. Of these, 143 genes are present on our promoter array (Figure 6). "; prov:wasQuotedFrom pubmed:15546613 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:15546613; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:32:34.894+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }